PATH | VRL
Menu

Emergence of Serogroup X Meningococcal Disease in Africa: Need for a Vaccine

This article, published in Vaccine, describes how and why serogroup X meningococcal disease has emerged in Africa in recent years. It asserts that while no licensed vaccine is available against serogroup X meningococci, following the introduction of a monovalent serogroup A conjugate vaccine (MenAfriVac®) in the meningitis belt and the upcoming introduction of pneumococcal conjugate vaccines, vaccine-based prevention of serogroup X may become a public health need. ABSTRACT ONLY. (Learn how users in developing countries can gain free access to journal articles.)

Author: Xie O, Pollard AJ, Mueller JE, Norheim G

Published: 2013

» Visit web page (English)

(Located at www.sciencedirect.com)

Citation: Xie O, Pollard AJ, Mueller JE, Norheim G. Emergence of Serogroup X Meningococcal Disease in Africa: Need for a Vaccine. Vaccine. 2013;31(27):2852-2861.

Resource types: Peer-reviewed journal

Diseases/vaccines: Meningococcus

Topics: Disease burden and surveillance, Disease/vaccine specific information

Regions: Africa